THOUSAND OAKS, California., Dec 3 2021 / PRNewswire / – Amgen (NASDAQ: AMGN) today announced that its board of directors has declared a $ 1.94 dividend per share for the first quarter of 2022. The dividend will be paid on March 8, 2022, to all registered shareholders at the close of business on February 15, 2022. This represents a 10% increase over that paid in each of the previous four quarters.
Amgen is committed to unlocking the potential of biology for critically ill patients by discovering, developing, manufacturing and delivering innovative human therapies. This approach begins with the use of tools such as advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas where unmet medical needs are high and leverages its expertise to find solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown into one of the world’s leading independent biotechnology companies, reaching millions of patients around the world, and developing a drug pipeline with disruptive potential.
Amgen is one of 30 companies that make up the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2021, Amgen was named one of the 25 Best Workplaces in the World â¢ by Fortune and Great Place to Work â¢ and one of the 100 Most Sustainable Companies in the World by Barron’s.
Amgen’s forward-looking statements
This press release contains forward-looking statements based on Amgen’s current expectations and beliefs. All statements, other than statements of historical fact, are statements that could be considered forward-looking statements, including any statement about the results, benefits and synergies of collaborations, or potential collaborations, with any other company ( including BeiGene, Ltd., Kyowa -Kirin Co., Ltd., or any collaboration to make therapeutic antibodies against COVID-19), Otezla performanceÂ® (apremilast) (including the anticipated sales growth of Otezla and the timing of the increase in non-GAAP EPS), the acquisition of Five Prime Therapeutics, Inc. or the acquisition of Teneobio, Inc., as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, legal, arbitration, policy, regulatory or clinical outcomes or practices, customer and prescriber models or practices, activities and outcomes reimbursement, the effects of pandemics or other widespread health problems such as the ongoing COVID-19 pandemic on our business, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K. and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise indicated, Amgen is providing this information as of the date of this press release and does not undertake to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual results may differ materially from those we expect. Our results may be affected by our ability to successfully market new and existing products nationally and internationally, clinical and regulatory developments regarding current and future products, sales growth of recently launched products, competition from other products , including biosimilars, difficulties or delays in the manufacture of our products, and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny, and reimbursement policies imposed by third party payers, including governments, private insurance plans and healthcare providers. managed and may be affected by regulatory, clinical and guideline developments and international trends towards the management of care and the containment of health care costs. In addition, our research, testing, pricing, marketing and other activities are subject to extensive regulation by domestic and foreign regulatory authorities. We or others may identify safety, side effects, or manufacturing issues with our products, including our devices, after they are released. Our business may be affected by government investigations, litigation and product liability claims. In addition, our business may be affected by the adoption of new tax legislation or by exposure to additional tax obligations. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could face significant penalties. Additionally, while we regularly obtain patents for our products and technology, the protection afforded by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in current litigation. and future in intellectual property. We conduct a substantial portion of our commercial manufacturing activities at a few key facilities, including Porto Rico, and also depend on third parties for a portion of our manufacturing operations, and supply limitations may restrict sales of some of our current products and the development of product candidates. An outbreak of disease or a similar threat to public health, such as COVID-19, and the public and government effort to mitigate the spread of such disease, could have a significant adverse effect on the supply of materials for our people. manufacturing activities, the distribution of our products, the marketing of our product candidates and our clinical trial operations, and any such event may have a material adverse effect on the development of our products, our product sales, our business and our operating results. We rely on collaborations with third parties for the development of some of our product candidates and for the marketing and sale of some of our commercial products. In addition, we compete with other companies for many of our commercialized products as well as for the discovery and development of new products. The discovery or identification of new product candidates or the development of new indications for existing products cannot be guaranteed and the transition from concept to product is uncertain; therefore, there can be no assurance that any particular product candidate or the development of a new indication for an existing product will be successful and become a commercial product. In addition, certain raw materials, medical devices and components of our products are supplied by exclusive third-party suppliers. Some of our distributors, customers and payers have significant purchasing leverage in their relationships with us. The discovery of material problems with a product similar to one of our products involving an entire class of products could have a material adverse effect on the sales of the affected products as well as on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technologies, and to integrate the operations of the companies or to support the products or technology that we have acquired, may fail. A failure, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our systems and data. The price of our shares is volatile and can be affected by a number of events. Global economic conditions may amplify certain risks that affect our business. Our business performance could affect or limit the ability of our board of directors to declare a dividend or our ability to pay a dividend or to repurchase our common shares. We may not be able to access capital and credit markets on terms that are favorable to us, if at all.
CONTACT: Amgen, Mille ChÃªnes
Megan Fox, 805-447-1423 (media)
Trish rowland, 805-447-5631 (media)
Arvind Sood, 805-447-1060 (investors)